Table 2.

Interventions in the ScvO₂-oriented group and lactate kinetics-oriented group during the treatment process

	Lactate kinetics group	ScvO2 group	P value
	n = 180	n = 180
RBC volume at 24 h, ml	144 ± 192	152 ± 193	0.705
Norepinephrine, %
1st day	46.1% (83/180)	46.7% (84/180)	0.916
2nd day	38.9% (70/180)	40.6% (73/180)	0.747
3rd day	27.2% (49/180)	30.3% (54/180)	0.560
Norepinephrine, μg/kg/h
	0 (0–4.46)	0 (0–7.75)	0.843
	0 (0–3.67)	0 (0–7.19)	0.1
	0 (0–0.57)	0 (0–2.45)	0.272
Dobutamine, %
1st day	2.2% (4/180)	3.9% (7/180)	0.358
2nd day	4.4% (8/180)	3.3% (6/180)	0.586
3rd day	3.9% (7/180)	3.3% (6/180)	0.778
Dobutamine, μg/kg/h
1st day	0 (0–0)	0 (0–0)	0.325
2nd day	0 (0–0)	0 (0–0)	0.263
3rd day	0 (0–0)	0 (0–0)	0.618
CVVH	26/154	36/144	0.163
Fluid volume, ml
0–2 h	563 (259–922)	590 (288–960)	0.539
2–4 h	1535 (1271–1778)	826 (631–1219)	<0.001
4–6 h	1687 (1476–1929)	1255 (1008–1537)	0.358
6–12 h	1688 (1173–1923)	1277 (962–1588)	<0.001
12–24 h	1510 (904–2087)	1236 (740–1808)	0.005
24–48 h	465 (341–606)	424 (279–552)	0.071
48–72 h	278 (159–410)	284 (226–324)	0.502

ScvO ₂ central venous oxygen saturation, CVVH continuous veno-venous hemofiltration